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2Abstract
Central to COVID-19 pathophysiology is an acute respiratory infection primarily manifesting 
as pneumonia. Two months into the COVID-19 outbreak, however, a retrospective study in 
China involving more than 200 participants revealed a neurological component to COVID-19 
in a subset of patients. The observed symptoms, the cause of which remains unclear, included 
impaired consciousness, skeletal muscle injury and acute cerebrovascular disease, and 
appeared more frequently in severe disease. Since then, findings from several studies have 
hinted at various possible neurological outcomes in COVID-19 patients. Here, we review the 
historical association between neurological complications and highly pathological 
coronaviruses including SARS, MERS and COVID-19. We draw from evidence derived from 
past coronavirus outbreaks, noting the similarities and differences between SARS and MERS 
and the current COVID-19 pandemic. We end by briefly discussing possible mechanisms by 
which the coronavirus impacts on the human nervous system, as well as neurology-specific 
considerations that arise from the repercussions of COVID-19.
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3Abbreviations
2019-nCoV = 2019 novel coronavirus;
ACE2 = angiotensin-converting enzyme 2;
ARDS = acute respiratory distress syndrome;
CNS = central nervous system; 
COVID-19 = Coronavirus Disease 19;
CRP = C-reactive protein
CSF = cerebrospinal fluid;
DPP4 = dipeptidyl peptidase 4;
MERS-CoV = Middle East respiratory syndrome coronavirus;
PNS = peripheral nervous system;
SARS-CoV = severe acute respiratory syndrome coronavirus;
SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2;
WHO = World Health Organisation. 
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Officially declared as a global pandemic by the World Health Organisation (WHO) on 11 
March 2020, the COVID-19 (Coronavirus Disease 19) outbreak has evolved at an 
unprecedented rate.  Following its emergence in Wuhan, the capital of the Hubei province, 
People’s Republic of China, in December 2019, the total number of confirmed coronavirus 
cases worldwide has already surpassed 2,900,000 as of 28 April 2020 [1], with actual figures 
believed to be even higher.  The virus responsible for the COVID-19 pandemic, initially 
designated as “2019-nCoV” (2019 novel coronavirus), was later renamed to “SARS-CoV-2” 
(severe acute respiratory syndrome coronavirus 2), given its similarity to the previous SARS-
CoV.
Whilst numerous comparisons can be drawn between SARS-CoV-2 and its predecessors – 
SARS-CoV and MERS-CoV (Middle East respiratory syndrome coronavirus) – responsible 
for the SARS and MERS epidemics, respectively, SARS-CoV-2 has unquestionably proved 
to be the most deadly.  The reported COVID-19 global death toll has now risen to more than 
200,000 since its first death in early January, far surpassing the combined reported death toll 
of SARS and MERS, which stands at less than 2,000 [2, 3].  Moreover, a considerable 
number of deaths from COVID-19 are taking place in the community and in care homes, 
which are commonly not being included in publicised national death tolls.  The reported 
number of COVID-19 cases and deaths in the People’s Republic of China has largely been 
exceeded by those residing elsewhere, with the USA and Europe now the new epicentres of 
this global health pandemic. 
Coronavirus: origin and transmission 
Coronaviruses, named after their characteristic crown-shaped microscopic appearance, are 
positive-sense single-stranded RNA viruses [4]. Taxonomically, they form part of the 
Coronavirinae subfamily (Coronaviridae family and Nidovirales order). The Coronavirinae 
subfamily consists of four genera, of which betacoronaviruses include many of the most 
5highly pathogenic coronaviruses known to man, including SARS-CoV, MERS-CoV and 
SARS-CoV-2. Similar to betacoronaviruses, alphacoronaviruses also infect humans and other 
mammals. The two other genera, gammacoronaviruses and deltacoronaviruses, are more 
commonly associated with birds.
Whilst the transmission of SARS-CoV and MERS-CoV has been attributed to market civets 
and dromedary camels, respectively, SARS-CoV-2 apparently emerged from the wet animal 
market in Wuhan.  All three diseases are, however, believed to originate from bats, although 
this has been difficult to prove [4]. Human-to-human transmission has also not been fully 
explained, with droplet transmission being most likely, and other mechanisms of spread 
including fomite and airborne transmission also implicated [5]. Asymptomatic COVID-19 
carriers and those with mild symptoms are thought to contribute to the massive transmission 
potential of COVID-19.
Typical clinical presentation
COVID-19, SARS and MERS primarily manifest as respiratory illnesses, which are 
occasionally accompanied by gastrointestinal manifestations [6]. Disease severity can range 
from an illness with only mild respiratory symptoms to severe acute respiratory distress 
syndrome (ARDS).  Incubation time is also variable, with symptoms taking from two days to 
as long as around two weeks to appear [7]. COVID-19 presents most frequently as a 
pneumonia, with its associated signs and symptoms, including fever, dry cough, and 
breathlessness, with characteristic radiological changes of bilateral lung opacities [6]. Whilst 
many of these also feature in SARS and MERS, COVID-19 has a propensity to cause lower 
respiratory tract infections, as suggested by the relatively less frequent occurrence of 
symptoms such as rhinorrhoea and sore throat. SARS and MERS are also more commonly 
linked to gastrointestinal symptoms, including diarrhoea.  Furthermore, it has become 
increasingly clear that all of these highly pathogenic coronaviruses affect the cardiovascular 
system, with evidence of both acute and chronic cardiovascular features [8].
The neurological complications of COVID-19, SARS and MERS
6Recent evidence suggests that COVID-19 pathophysiology may also involve the nervous 
system. A retrospective study in China involving more than 200 participants revealed that a 
subset of COVID-19 patients experienced neurological symptoms [9]. These included 
impaired consciousness, acute cerebrovascular disease and skeletal muscle symptoms, 
suggesting the involvement of both the central nervous system (CNS) and peripheral nervous 
system (PNS).  The observed symptoms were more likely to be present in patients suffering 
from severe disease. Other possible PNS symptoms included hypogeusia and hyposmia. The 
link between these neurological symptoms and patient outcome could not be investigated, as 
patients were still acutely hospitalised at the time of the publication. Another study by the 
same group reported that in 13 patients COVID-19 infection was followed by acute 
cerebrovascular disease, including ischaemic stroke, cerebral venous sinus thrombosis and 
cerebral haemorrhage [10]. These features were again more common in severe disease and 
older patients. 
Consistent with the findings from China, neurological manifestations were also reported by a 
second study in France, which followed 58 COVID-19 patients admitted to hospital owing to 
acute respiratory distress syndrome [11]. 84% experienced neurological symptoms at various 
timepoints, from ICU admission to discontinuation of neuromuscular blockade. The 
neurological features included evidence of encephalopathy, corticospinal tract dysfunction, 
agitation and delirium. MRI and perfusion brain imaging conducted in a small subset of 
patients also revealed leptomeningeal enhancement and bilateral frontotemporal 
hypoperfusion, and two patients also had evidence of a small acute ischaemic stroke. As we 
await additional studies to further characterise the associated neurological manifestations of 
COVID-19, an increasing number of individual case reports have emerged, describing acute 
neurological disorders ranging from Guillain-Barré syndrome and acute myelitis to acute 
haemorrhagic necrotising encephalopathy in patients with COVID-19 [12-18]. 
Whilst relatively fewer neurological associations have been made during past coronavirus 
epidemics, a number of case reports of SARS patients have documented the development of 
seizures, myopathy and rhabdomyolysis [19-23]. In one study involving 206 SARS patients, 
five cases of acute cerebrovascular disease were reported [24]. Whether this merits a parallel 
being drawn between SARS and COVID-19 pathophysiology is, however, debatable. Noting 
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with a differential diagnosis, the presence of viral RNA, in both cerebrospinal fluid (CSF) 
[19, 21] as well as in autopsied brain tissue [23], nevertheless points to a neurotropic 
component to the SARS coronavirus.
Neurological disorders have also been reported during the MERS outbreak, with neuropathy, 
delirium and acute cerebrovascular disease being described by several case reports [25-27]. 
Another study involving 70 MERS patients further reported confusion and seizures in 18 and 
6 of the participants, respectively [28], although interpreting such findings again warrants 
caution. In contrast to SARS, little evidence currently exists for the presence of the MERS 
coronavirus in CSF. This also appears to be the case for COVID-19, where evidence for viral 
presence in CSF is still limited to a single case report [15], with other studies unable to 
replicate these findings thus far [11, 12, 18]. 
ACE2 receptor
Whilst MERS-CoV infects cells by binding to the dipeptidyl peptidase 4 (DPP4) receptor, 
SARS-CoV instead acts via the angiotensin-converting enzyme 2 (ACE2) receptor [4],  
ACE2, which is a membrane-bound protein expressed across different organs, including 
skeletal muscle and the brain [29, 30], has also recently been found to be the functional 
receptor of SARS-CoV-2 [31].  Similar to SARS-CoV, SARS-CoV-2 attaches to the host cell 
membrane through interaction between a spike protein and the host ACE2 receptor [32, 33]. 
Notably, the binding affinity of the SARS-CoV-2 spike protein to ACE2 has been found to be 
significantly higher than that of the SARS-CoV spike protein [32], although the implications 
of this remain to be established. Whilst still controversial, ACE inhibitors and ibuprofen may 
increase ACE2 levels [34], potentially facilitating COVID-19 infection, and are of interest 
because of their use in the management of migraine.
Neurotropism
It is also currently unclear how SARS-CoV-2 invades the human CNS.  One suggested 
mechanism is through haematogenous dissemination, whereby the virus crosses into the CNS 
8from the bloodstream by infecting endothelial cells or leukocytes [35]. Another possible 
pathway is via retrograde neuronal routes, in which the virus gains access to the CNS by 
infecting peripheral neurons [35].  Animal studies have demonstrated that SARS-CoV could 
reach the brain via an olfactory route, promoting neurodegeneration [33]. Emerging evidence 
from two studies, both available via bioRxiv preprint, and therefore yet to be peer-reviewed, 
suggests that SARS-CoV-2 also gains access to the CNS via the olfactory pathway, with 
concordant results demonstrating the expression of both the ACE2 receptor and the spike 
protein protease TMPRSS2, which is also required for SARS-CoV-2 entry, by specific 
subsets of cells present in the olfactory region [36, 37]. Whilst reports of SARS-related 
olfactory neuropathy are sparse [38], anosmia and hyposmia are increasingly being 
recognised as key features of COVID-19 infection, often as a presenting symptom [9, 39-43]. 
Thus, these studies could potentially provide promising avenues for future research aimed at 
improving our understanding of SARS-CoV-2 neurotropism.
Potential mechanisms of neurological manifestations of COVID-19
Although various lines of evidence support the involvement of the human nervous system in 
SARS, MERS and COVID-19, it remains difficult to ascertain how the different neurological 
features relate to the overall pathophysiology; namely, whether they result directly or 
indirectly from viral infection, or arise through other mechanisms, such as hypoxia, sepsis or 
multi-organ failure. 
One possible mechanism is via an immune-related pathway. COVID-19 appears to possess an 
important immune component, with several studies reporting findings such as lymphopenia 
and raised C-reactive protein (CRP) levels in COVID-19 patients [6, 44, 45]. Cytokine storm 
syndromes, including secondary haemophagocytic lymphohistiocytosis (sHLH), have 
recently gained considerable attention as an uncommon, but fatal, complication of COVID-19 
patients, particularly in those with severe disease [46]. Hence, patients with severe COVID-
19 are increasingly being monitored for raised ferritin levels, suggestive of 
hyperinflammation.  
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patients presenting with CNS symptoms compared to those without CNS involvement [9, 10]. 
Patients with severe disease were also found to possess higher levels of D-dimer, a marker of 
a hypercoagulable state and of endogenous fibrinolysis, which could possibly explain why 
acute cerebrovascular disease more commonly develops in such patients [9, 10]. It has 
therefore been suggested that anti-inflammatory pathways could potentially be targeted early 
on, aiming to reduce the risk of acute cerebrovascular disease [10].
Neurology-specific considerations
There are a number of specific patient management and service delivery considerations that 
are worth touching on [47-50].  The COVID-19 pandemic has stimulated the rapid 
dissemination of authoritative and practical information by representative neurology bodies 
globally, providing, for instance, consensus guidance advising about isolation strategies for 
high-risk patients, and the management considerations for patients on immunosuppressive 
agents. The scope of these guidelines will change based on emerging data from our 
colleagues in other specialties, such as whether thromboprophylaxis regimes, or the process 
of taking informed consent need to be altered in patients requiring intravenous 
immunoglobulin therapy, given the concerns about prothrombotic states in COVID-19.  
Moreover, given the possibility that a significant driver of pathology may be related to an 
overactive immune state, it remains an open question whether certain immunosuppressive 
agents may be beneficial, such as has been suggested in a case report of ocrelizumab in 
multiple sclerosis [51]. Owing to outpatient departments being closed to mitigate COVID-19 
transmission, several academic centres, hospitals and clinics have rapidly adopted new 
strategies for managing neurology patients, and it is heartening to see those neurological 
centres lacking in infrastructure for tele-medicine catching up with those that did, in a 
concerted effort to maintain acute neurology and outpatient services.     
Concluding remarks
The neurology of COVID-19 and other coronavirus-related infections is a rapidly evolving 
area of medicine. Whilst most studies in the past, including those relating to SARS and 
MERS, have mainly involved small patient samples, the latest evidence on COVID-19 
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suggests that neurological events may occur in a significant proportion of patients. Further 
studies will allow for an assessment of the presence of any long-term neurological sequelae.  
There is a need for record-linkage studies that can establish varying degrees of associations 
between the incidence, severity and prognosis of COVID-19, and specific 
immunosuppressive disease modifying therapies, that would help in risk stratification and 
risk modification exercises for the management of patients with neuroinflammatory 
disorders; this would be especially useful if there were a second wave of COVID-19 illness.  
Finally, improving our understanding of the neurobiology of coronaviruses could augment 
our knowledge of neurological disorders with potential viral associations, such as viral 
encephalitis and multiple sclerosis. 
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Highlights
 COVID-19 is caused by a highly pathogenic coronavirus named “SARS-CoV-2”.
 COVID-19 pathophysiology is primarily defined by acute respiratory illness.
 Several studies have revealed a possible neurological component to COVID-19.
 Various neurological manifestations have also been reported for SARS and MERS.
 Further research into the importance of neurological manifestations in COVID-19 is 
needed.
